Fifteen years ago, an HIV vaccine trial conducted in Thailand and sponsored by the U.S. Army found something no other HIV vaccine trial ever had: a regimen that seemed to work.
A combination of two experimental vaccines reduced the rate of new HIV infections in the phase 3 trial by more than 31% compared with placebo, according to results announced in 2009.
More than a decade later, however, a trial of a similar vaccine regimen adapted to match HIV viruses in southern Africa was stopped by the NIH because it was not preventing infections. In the years since, every other late-stage HIV vaccine trial has met the same fate — ending without success.
Developing an effective HIV vaccine has been complicated for numerous reasons, including the makeup of the virus itself, which is prone to mutation and difficult to target.
Things could get even harder, experts told Healio.
Read the full story at Healio.
Source : Healio
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.